Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study
Oncology Research · 2026
DOI: 10.32604/or.2025.073891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Keiko Yanagihara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan. Hauptthemen laut MEDLINE: Piperazines, Breast Neoplasms, Pyridines, Antineoplastic Combined Chemotherapy Protocols. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.
- Department of Pharmacy, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.
- Department of Pathology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.
Zitieren
APA
Yanagihara, K., Yoshida, M., Awaji, K., Yamakawa, T., Kato, S., Tamura, M., & Nagata, K. (2026). Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study. Oncology Research. https://doi.org/10.32604/or.2025.073891
Vancouver
Yanagihara K, Yoshida M, Awaji K, Yamakawa T, Kato S, Tamura M, et al. Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study. Oncology Research. 2026. doi:10.32604/or.2025.073891
BibTeX
@article{Yanagihara2026,
author = {Yanagihara, Keiko and Yoshida, Masato and Awaji, Kensaku and Yamakawa, Tamami and Kato, Sena and Tamura, Miki and Nagata, Koji},
title = {Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2025.073891}
}
EUVIMED